Skip to content
    ArrowMark Partners logo

    ArrowMark Partners

    Denver, Colorado, United StatesFounded 2007
    www.arrowmarkpartners.comLinkedIn
    Biotech & Life SciencesHealthcare

    ArrowMark Partners is a privately held, employee-owned investment management firm founded in 2007 and headquartered in Denver, Colorado. The firm manages over $18 billion in assets across credit (private credit, alternative credit, CLOs/leveraged loans), real estate (CRE structured finance, bridge lending), and equity (long-only, life science, hedged equity) strategies, with a life science arm focused on early-stage biotech investing and company creation.

    45% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $127.2M (across 54 rounds with reported amounts).

    Find people at ArrowMark Partners on Goldilocks AI

    Portfolio

    41

    Fund Size

    $1.1B

    Top Stage

    Series B

    Last 12 Mo

    1

    Team

    BS

    Brian Schaub

    Partner, Portfolio Manager

    CM

    Chad Meade

    Partner, Portfolio Manager

    DC

    David Corkins

    Partner, Portfolio Manager

    KA

    Kaelyn Abrell

    Partner, Portfolio Manager

    KR

    Karen Reidy

    Partner, Portfolio Manager

    KR

    Kirk Reid

    Partner, Chief Operations & Technology Officer

    RB

    Rob Brown

    Partner, Portfolio Manager

    SB

    Sanjai Bhonsle

    Partner, Portfolio Manager

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    55 investments
    CompanyRoundAmountDate
    Skyryse logoSkyryseSeries C$300MFeb 2026
    Arbor Biotechnologies logoArbor BiotechnologiesSeries C$73.9MMar 2025
    530 Fifth Avenue logo530 Fifth AvenueSeries D$152MJan 2025
    Zenas BioPharma logoZenas BioPharmaSeries C$200MMay 2024
    Freenome logoFreenomeGrowth$254MFeb 2024
    SmartLabs logoSmartLabsSeries C$48MJan 2024
    Zenas BioPharma logoZenas BioPharmaSeries C$200MJan 2024
    Neurogene logoNeurogeneSeries B$115MJan 2024
    Talis logoTalisIpo$220MJan 2023
    Beta Bionics logoBeta BionicsSeries C$57MFeb 2022
    Simcha Therapeutics logoSimcha TherapeuticsSeries B$40MJan 2022
    Arbor Biotechnologies logoArbor BiotechnologiesSeries B$215MNov 2021
    Fyllo logoFylloSeries C$40MNov 2021
    Skyryse logoSkyryseSeries B$205MOct 2021
    Formation Bio logoFormation BioSeries C$156MSep 2021
    BBinx HealthSeries E$104MMay 2021
    Adagio logoAdagioSeries C$336MApr 2021
    Absci logoAbsciGrowth$125MMar 2021
    Dataminr logoDataminrSeries F$475MMar 2021
    Amunix logoAmunixSeries B$117MMar 2021
    AAmunix PharmaceuticalsSeries B$117MMar 2021
    AAmunix PharmaceuticalsSeries B$117MJan 2021
    MaxCyte logoMaxCyteGrowth—Jan 2021
    NexImmune logoNexImmuneSeries A$86MJan 2021
    Arbor Biotechnologies logoArbor BiotechnologiesSeries B$215MJan 2021
    Page 1 of 3

    Top Co-Investors

    Casdin Capital11 shared
    Redmile Group11 shared
    Perceptive Advisors10 shared
    Polaris Partners9 shared
    RA Capital Management8 shared
    Venrock7 shared
    Viking Global Investors7 shared
    T. Rowe Price6 shared
    Longitude Capital6 shared
    Omega Funds6 shared
    Fidelity Investments5 shared
    OrbiMed5 shared
    Franklin Templeton5 shared
    BlackRock Private Equity Partners5 shared
    Avidity Partners5 shared
    Ridgeback Capital5 shared
    Cormorant Asset Management5 shared
    Wellington Management5 shared
    SR One5 shared
    S324 shared

    Last updated: 7 October 2026